Literature DB >> 2548818

Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B.

J Van Cutsem1, F Van Gerven, J Fransen, P A Janssen.   

Abstract

Nonpredisposed Albino guinea pigs were infected intravenously with Rhizopus microsporus var. rhizopodiformis or with Rhizopus oryzae. Both strains were highly pathogenic. They killed all control animals between days 4 and 7 and between days 5 and 9 after infection, respectively. All animals presented invasion of almost all internal organs and skin eruptions developing into ulcers. Oral treatment with ketoconazole, itraconazole, fluconazole or saperconazole was inefficacious. Parenteral treatment with amphotericin B prolonged survival and was life-saving in 9 out of 12 guinea pigs infected with Rh. microsporus var. rhizopodiformis and in 5 out of 12 infected with Rh. oryzae. More active therapy is needed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548818     DOI: 10.1159/000238681

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  10 in total

1.  Zygomycotic gangrenous cellulitis in a patient with non-insulin dependent diabetes mellitus.

Authors:  O Zimhony; E Israeli; S D Malnick; A Pansky; P Cohen; D Geltner
Journal:  West J Med       Date:  1998-03

Review 2.  Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment.

Authors:  R Herbrecht; S Neuville; V Letscher-Bru; S Natarajan-Amé; O Lortholary
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

3.  Rhino-orbital-cerebral mucormycosis.

Authors:  Maria N Gamaletsou; Nikolaos V Sipsas; Emmanuel Roilides; Thomas J Walsh
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

4.  Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.

Authors:  Eric Dannaoui; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 5.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

6.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

7.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 8.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

9.  In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens.

Authors:  M Otcenásek; V Buchta
Journal:  Mycopathologia       Date:  1994-12       Impact factor: 2.574

Review 10.  Animal models of zygomycosis--Absidia, Rhizopus, Rhizomucor, and Cunninghamella.

Authors:  K Kamei
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.